

DECEMBER 2019

INOVIO coronavirus experts learn about a novel coronavirus (SARS-CoV-2) which caused an outbreak of respiratory disease in Wuhan, China, now referred to as COVID-19

JANUARY 10/11, 2020

Chinese researchers share the genetic sequence of the novel coronavirus on 1/10

INOVIO designs DNA vaccine INO-4800 in three hours after receiving the genetic sequence late in the evening on 1/10 using its proprietary DNA medicines platform technology

INO-4800 was designed to precisely match the DNA sequence of the virus just after midnight on 1/11

JANUARY 10 - JANUARY 23, 2020

INOVIO coronavirus experts race to manufacture INO-4800 and begin preclinical testing and clinical trial design

JANUARY 23, 2020

INOVIO receives a grant of up to \$9 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to fund ongoing preclinical and initial clinical development of INO-4800



JANUARY 23 - FEBRUARY 29, 2020

Preclinical testing continues, with immune responses generated in animal models; initial preclinical data submitted to peer-reviewed journal; human clinical trial designs developed and shared with regulators

MARCH 2020

Ongoing preclinical studies, including challenge studies; initial preclinical data “under consideration” at peer-reviewed journal; human clinical trial designs finalized; 3,000 human trial doses prepared for clinical trials in the U.S., China, and South Korea; large-scale manufacturing plans developed


MARCH 12, 2020

INOVIO announces \$5 million grant from the Bill & Melinda Gates Foundation to continue advancing the development of INO-4800, specifically to accelerate the testing and scale up of INOVIO’s proprietary smart device CELLECTRA® 3PSP



MARCH 26, 2020

INOVIO announces the Department of Defense (DOD) awarded Ology Bioservices an \$11.9 million contract to work with INOVIO on DNA technology transfer to rapidly manufacture INO-4800 for the DOD for upcoming clinical trials



APRIL 6 - 23, 2020

INOVIO announces initiation of Phase 1 human clinical trial in the U.S. following authorization by the U.S. Food and Drug Administration of its Investigational New Drug (IND) application

U.S. study fully enrolled 40 healthy volunteers; study sites are the University of Pennsylvania and a clinic in Kansas City, MO

Clinical trials and preclinical challenge studies continue

MAY 2020

Preclinical data published in peer-reviewed journal Nature Communications

FALL 2020

In June, U.S. Phase 1 trial results to be announced

Phase 2/3 trial expected to begin

Human clinical trials expected to begin in China and South Korea*

ONGOING

INO-4800 COVID-19 DNA vaccine production and scale up underway*

*Pending appropriate regulatory guidance and external funding

